2024
54148 Characteristics of Real-world Patients With Psoriasis Prescribed Guselkumab or Interleukin-17 Inhibitors: Data From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)
Strober B, Augustin M, Tada Y, Lafferty K, Skobelev E, Langholff W, Fakharzadeh S, Gniadecki R. 54148 Characteristics of Real-world Patients With Psoriasis Prescribed Guselkumab or Interleukin-17 Inhibitors: Data From the Psoriasis Longitudinal Assessment and Registry (PSOLAR). Journal Of The American Academy Of Dermatology 2024, 91: ab152. DOI: 10.1016/j.jaad.2024.07.605.Peer-Reviewed Original Research
2021
Drug survival of ixekizumab, TNF inhibitors, and other IL‐17 inhibitors in real‐world patients with psoriasis: The Corrona Psoriasis Registry
Lockshin B, Cronin A, Harrison R, McLean R, Anatale‐Tardiff L, Burge R, Zhu B, Malatestinic W, Atiya B, Murage M, Gallo G, Strober B, Van Voorhees A. Drug survival of ixekizumab, TNF inhibitors, and other IL‐17 inhibitors in real‐world patients with psoriasis: The Corrona Psoriasis Registry. Dermatologic Therapy 2021, 34: e14808. PMID: 33491259, PMCID: PMC8047872, DOI: 10.1111/dth.14808.Peer-Reviewed Original ResearchConceptsCorrona Psoriasis RegistryIL-17 inhibitorsIL-17iTNF inhibitorsReal-world patientsDrug survivalHazard ratioPsoriasis RegistryDrug discontinuationDrug initiationLower riskBiologic experienceIxekizumab groupsPsO patientsSevere PsONaïve patientsMean ageIxekizumabPatientsReal-world settingDiscontinuationPsoriasisSurvivalRegistryInhibitors